\-\ Texto\\:\\ \ \(0\)\
\-\ elevated\\ rheumatoid\\ factor\ \(0\)\
\-\ decreased\\ renal\\ function\\ \\(increased\\ serum\\ creatinine\\ and\\ decreased\\ gfr\\)\ \(0\)\
\-\ nsaids\\ have\\ been\\ the\\ cornerstone\\ of\\ therapy\\ by\\ reducing\\ pain\\ and\\ inflammation\\ and\\ allowing\\ improvements\\ in\\ mobility\\ and\\ function\\.\\ typically\\,\\ the\\ use\\ of\\ nsaids\\ alone\\ as\\ single\\ agents\\ in\\ ra\\ should\\ be\\ reserved\\ for\\ mild\\,\\ well\\-controlled\\ disease\\.\\ cox\\-2\\ inhibitors\\ may\\ be\\ more\\ effective\\ in\\ controlling\\ inflammation\\.\ \(0\)\
\-\ there\\ are\\ also\\ many\\ disease\\-modifying\\ drug\\ regimens\\ present\\ such\\ as\\ methotrexate\\,\\ hydroxychloroquine\\,\\ gold\\,\\ d\\-penicillamine\\,\\ sulfasalazine\\,\\ cyclosporine\\ a\\,\\ minocycline\\,\\ azathioprine\\,\\ leflunomide\\,\\ infliximab\\,\\ and\\ etanercept\\.\ \(0\)\
\-\ plain\\ radiographs\\:\ \(0\)\
\-\ both\\ hands\\ demonstrate\\ bilateral\\ symmetric\\ severe\\ proximal\\ \\(mcp\\)\\ joint\\ space\\ destruction\\ with\\ periarticular\\ osteopenia\\ and\\ ulnar\\ subluxation\\ of\\ the\\ 1st\\ and\\ 2nd\\ proximal\\ phalanges\\ on\\ their\\ respective\\ metacarpals\\.\ \(0\)\
\-\ rheumatoid\\ arthritis\ \(67\)\
\-\ rheumatoid\\ arthritis\ \(67\)\
\-\ psoriatic\\ arthritis\ \(11\)\
\-\ amyloidosis\ \(26\)\
\-\ polyarteritis\\ nodosa\ \(6\)\
\-\ viral\\ arthritis\\ \\(eg\\,\\ rubella\\,\\ hepatitis\\ b\\,\\ parvovirus\\)\ \(0\)\
\-\ whipple\\ disease\ \(0\)\
\-\ scleroderma\ \(13\)\
\-\ paraneoplastic\\ syndromes\ \(3\)\
\-\ multicentric\\ reticulohistiocytosis\ \(0\)\
\-\ osteoarthritis\\ \\(erosive\\)\ \(0\)\
\-\ 53\\ y\\.o\\.\\ woman\\ with\\ bilateral\\ hand\\ pain\\ that\\ is\\ severe\\ in\\ nature\\ and\\ continues\\ to\\ progress\\ in\\ severity\\.\\ despite\\ many\\ treatment\\ modalities\\,\\ she\\ has\\ had\\ persistent\\ and\\ chronic\\ pain\\ that\\ limits\\ her\\ quality\\ of\\ life\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ arthritis\\:\\ 0\\.0715829892165291\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.059358748983161305\ \(0\)\
\-\ nsaids\\:\\ 0\\.04520417455466209\ \(0\)\
\-\ minocycline\\:\\ 0\\.04321332560767891\ \(0\)\
\-\ reticulohistiocytosis\\:\\ 0\\.04321332560767891\ \(0\)\
\-\ cornerstone\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ cox\\-2\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ disease\\-modifying\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ leflunomide\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ parvovirus\\:\\ 0\\.039815545310816436\ \(0\)\
\-\ d\\-penicillamine\\:\\ 0\\.037827971251462686\ \(0\)\
\-\ well\\-controlled\\:\\ 0\\.03641776501395396\ \(0\)\
\-\ hydroxychloroquine\\:\\ 0\\.03641776501395396\ \(0\)\
\-\ infliximab\\:\\ 0\\.03641776501395396\ \(0\)\
\-\ etanercept\\:\\ 0\\.03641776501395396\ \(0\)\
\-\ inflammation\\:\\ 0\\.03562485170269033\ \(0\)\
\-\ function\\:\\ 0\\.0355153095399636\ \(0\)\
\-\ improvements\\:\\ 0\\.035323924076139206\ \(0\)\
\-\ sulfasalazine\\:\\ 0\\.035323924076139206\ \(0\)\
\-\ many\\:\\ 0\\.03443346584222963\ \(0\)\
\-\ respective\\:\\ 0\\.03443019095460021\ \(0\)\
\-\ cyclosporine\\:\\ 0\\.03367455036721169\ \(0\)\
\-\ azathioprine\\:\\ 0\\.03367455036721169\ \(0\)\
\-\ gfr\\:\\ 0\\.03301998471709148\ \(0\)\
\-\ polyarteritis\\:\\ 0\\.03301998471709148\ \(0\)\
\-\ rubella\\:\\ 0\\.03301998471709148\ \(0\)\
\-\ whipple\\:\\ 0\\.03301998471709148\ \(0\)\
\-\ multicentric\\:\\ 0\\.03301998471709148\ \(0\)\
\-\ controlling\\:\\ 0\\.03244261689524646\ \(0\)\
\-\ regimens\\:\\ 0\\.03192614377927673\ \(0\)\
\-\ nodosa\\:\\ 0\\.031458937015530035\ \(0\)\
\-\ inhibitors\\:\\ 0\\.031032410657737732\ \(0\)\
\-\ reducing\\:\\ 0\\.03064004444365177\ \(0\)\
\-\ metacarpals\\:\\ 0\\.03064004444365177\ \(0\)\
\-\ paraneoplastic\\:\\ 0\\.030276770070349214\ \(0\)\
\-\ periarticular\\:\\ 0\\.028289196010995464\ \(0\)\
\-\ quality\\:\\ 0\\.028289196010995464\ \(0\)\
\-\ reserved\\:\\ 0\\.027843255921751707\ \(0\)\
\-\ gold\\:\\ 0\\.027634630360875254\ \(0\)\
\-\ phalanges\\:\\ 0\\.027634630360875254\ \(0\)\
\-\ mcp\\:\\ 0\\.02724226414678929\ \(0\)\
\-\ allowing\\:\\ 0\\.02705726253903024\ \(0\)\
\-\ methotrexate\\:\\ 0\\.026706973499902077\ \(0\)\
\-\ mobility\\:\\ 0\\.026540789423060502\ \(0\)\
\-\ scleroderma\\:\\ 0\\.026540789423060502\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.026224424123366525\ \(0\)\
\-\ severe\\:\\ 0\\.025777547059470628\ \(0\)\
\-\ psoriatic\\:\\ 0\\.025254690087435548\ \(0\)\
\-\ proximal\\:\\ 0\\.0251523841343825\ \(0\)\
\-\ eg\\:\\ 0\\.025130583185551773\ \(0\)\
\-\ modalities\\:\\ 0\\.025130583185551773\ \(0\)\
\-\ decreased\\:\\ 0\\.0249093764972996\ \(0\)\
\-\ erosive\\:\\ 0\\.02489141571413299\ \(0\)\
\-\ 1st\\:\\ 0\\.02466337642180508\ \(0\)\
\-\ agents\\:\\ 0\\.02455321536370676\ \(0\)\
\-\ osteopenia\\:\\ 0\\.024340053050276665\ \(0\)\
\-\ hepatitis\\:\\ 0\\.024036742247737018\ \(0\)\
\-\ syndromes\\:\\ 0\\.023939670545304766\ \(0\)\
\-\ creatinine\\:\\ 0\\.023844483849926816\ \(0\)\
\-\ effective\\:\\ 0\\.023844483849926816\ \(0\)\
\-\ progress\\:\\ 0\\.023659482242167764\ \(0\)\
\-\ subluxation\\:\\ 0\\.023309193203039605\ \(0\)\
\-\ ra\\:\\ 0\\.022903841654779242\ \(0\)\
\-\ severity\\:\\ 0\\.02275064291211206\ \(0\)\
\-\ alone\\:\\ 0\\.022675802362451335\ \(0\)\
\-\ 53\\:\\ 0\\.022602087277331043\ \(0\)\
\-\ ulnar\\:\\ 0\\.022049168188383275\ \(0\)\
\-\ continues\\:\\ 0\\.021856909790573073\ \(0\)\
\-\ hands\\:\\ 0\\.021671908182814014\ \(0\)\
\-\ drug\\:\\ 0\\.02149363541727051\ \(0\)\
\-\ factor\\:\\ 0\\.021378289841730343\ \(0\)\
\-\ \\,\\:\\ 0\\.021232162001355873\ \(0\)\
\-\ viral\\:\\ 0\\.02110126920318455\ \(0\)\
\-\ 2nd\\:\\ 0\\.020890399668460576\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.02078827179148586\ \(0\)\
\-\ destruction\\:\\ 0\\.02068822830309759\ \(0\)\
\-\ bilateral\\:\\ 0\\.02033154636582788\ \(0\)\
\-\ serum\\:\\ 0\\.020216522263418406\ \(0\)\
\-\ nature\\:\\ 0\\.01982761666421977\ \(0\)\
\-\ b\\:\\ 0\\.01974522882933555\ \(0\)\
\-\ despite\\:\\ 0\\.019467310477979935\ \(0\)\
\-\ symmetric\\:\\ 0\\.01913168401093356\ \(0\)\
\-\ their\\:\\ 0\\.01833502259182682\ \(0\)\
\-\ life\\:\\ 0\\.01827412788595154\ \(0\)\
\-\ limits\\:\\ 0\\.017265752937460813\ \(0\)\
\-\ hand\\:\\ 0\\.017216732921114815\ \(0\)\
\-\ single\\:\\ 0\\.016978726914168782\ \(0\)\
\-\ persistent\\:\\ 0\\.016707581629933233\ \(0\)\
\-\ use\\:\\ 0\\.016556074093349523\ \(0\)\
\-\ pain\\:\\ 0\\.01534717893427551\ \(0\)\
\-\ typically\\:\\ 0\\.014786400830911628\ \(0\)\
\-\ that\\:\\ 0\\.014470399299596306\ \(0\)\
\-\ elevated\\:\\ 0\\.014212335104701289\ \(0\)\
\-\ \\(\\:\\ 0\\.014163955416546284\ \(0\)\
\-\ \\)\\:\\ 0\\.01399093513947657\ \(0\)\
\-\ space\\:\\ 0\\.013855671603316836\ \(0\)\
\-\ disease\\:\\ 0\\.013693505306036314\ \(0\)\
\-\ plain\\:\\ 0\\.013604233885730807\ \(0\)\
\-\ joint\\:\\ 0\\.013546221838441574\ \(0\)\
\-\ should\\:\\ 0\\.013353963440631372\ \(0\)\
\-\ radiographs\\:\\ 0\\.013266033535304571\ \(0\)\
\-\ such\\:\\ 0\\.013094768577651237\ \(0\)\
\-\ be\\:\\ 0\\.012919183562195383\ \(0\)\
\-\ as\\:\\ 0\\.012672328489158115\ \(0\)\
\-\ her\\:\\ 0\\.012595155188651645\ \(0\)\
\-\ renal\\:\\ 0\\.01258566445812779\ \(0\)\
\-\ y\\.o\\:\\ 0\\.012090095257777942\ \(0\)\
\-\ chronic\\:\\ 0\\.011798968788759804\ \(0\)\
\-\ she\\:\\ 0\\.01175875559536359\ \(0\)\
\-\ been\\:\\ 0\\.011396053379725447\ \(0\)\
\-\ therapy\\:\\ 0\\.01119921958941477\ \(0\)\
\-\ mild\\:\\ 0\\.011030654185936946\ \(0\)\
\-\ both\\:\\ 0\\.010697058777873143\ \(0\)\
\-\ more\\:\\ 0\\.01047635445741258\ \(0\)\
\-\ in\\:\\ 0\\.010328363483829777\ \(0\)\
\-\ increased\\:\\ 0\\.010247474420586548\ \(0\)\
\-\ woman\\:\\ 0\\.009675994840631892\ \(0\)\
\-\ demonstrate\\:\\ 0\\.009639471281044316\ \(0\)\
\-\ present\\:\\ 0\\.009460827225155299\ \(0\)\
\-\ may\\:\\ 0\\.009187884161265312\ \(0\)\
\-\ have\\:\\ 0\\.009070774893946528\ \(0\)\
\-\ had\\:\\ 0\\.009038479506081902\ \(0\)\
\-\ treatment\\:\\ 0\\.008478514507847486\ \(0\)\
\-\ also\\:\\ 0\\.008257939184657604\ \(0\)\
\-\ and\\:\\ 0\\.007941573782303755\ \(0\)\
\-\ has\\:\\ 0\\.007866176325952342\ \(0\)\
\-\ by\\:\\ 0\\.006974857368847425\ \(0\)\
\-\ there\\:\\ 0\\.006233899786593082\ \(0\)\
\-\ are\\:\\ 0\\.005710166041811773\ \(0\)\
\-\ \\:\\:\\ 0\\.005540562823483652\ \(0\)\
\-\ for\\:\\ 0\\.003574059552170172\ \(0\)\
\-\ on\\:\\ 0\\.0035484853547324904\ \(0\)\
\-\ is\\:\\ 0\\.002756327345023165\ \(0\)\
\-\ of\\:\\ 0\\.0022843882509409495\ \(0\)\
\-\ to\\:\\ 0\\.00209347111981856\ \(0\)\
\-\ the\\:\\ 0\\.002033077716229791\ \(0\)\
\-\ a\\:\\ 0\\.0019441166755813787\ \(0\)\
\-\ \\.\\:\\ 0\\.0013921386704841675\ \(0\)\
\-\ with\\:\\ 0\\.0011470997655871542\ \(0\)\
